張長武

[摘要]目的 探討蘭索拉唑與泮托拉唑治療胃潰瘍的臨床效果及安全性。方法 選取2015年1月～2018年10月我院收治的56例胃潰瘍患者作為研究對象，按照隨機分組方法分為實驗組（28例）與對照組（28例）。實驗組采用蘭索拉唑靜脈滴注治療，對照組采用泮托拉靜脈滴注治療。比較兩組的臨床療效、臨床癥狀積分、不良反應(yīng)發(fā)生情況。結(jié)果 實驗組的治療總有效率（96.43%）高于對照組（75.00%），差異有統(tǒng)計學(xué)意義（P<0.05）。實驗組的臨床癥狀積分為（1.52±0.28）分，低于對照組的（2.74±0.46）分，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組的不良反應(yīng)總發(fā)生率比較，差異無統(tǒng)計學(xué)意義（P>0.05）。結(jié)論 蘭索拉唑與泮托拉唑治療胃潰瘍能夠明顯改善患者的臨床癥狀，快速緩解其疼痛，臨床效果顯著。蘭索拉唑在臨床療效、臨床癥狀積分、不良反應(yīng)方面更優(yōu)于泮托拉唑，安全性高，值得臨床推廣。

[關(guān)鍵詞]蘭索拉唑;泮托拉唑;胃潰瘍;臨床療效

[中圖分類號] R573.1? ? ? ? ? [文獻標(biāo)識碼] A? ? ? ? ? [文章編號] 1674-4721（2019）7（c）-0073-03

[Abstract] Objective To explore the clinical effect and safety of Lansoprazole and Pantoprazole in the treatment of gastric ulcer. Methods All of 56 patients with gastric ulcer admitted to our hospital from January 2015 to October 2018 were selected as the study subjects. According to the method of random grouping， they were divided into the experimental group （28 cases） and control group （28 cases）. The experimental group was treated with Lansoprazole for intravenous drip， while the control group was treated with Pantoprazole for intravenous drip. The clinical efficacy， clinical symptom score and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the experimental group （96.43%） was higher than that of the control group （75.00%）， and the difference was statistically significant （P<0.05）. The score of clinical symptoms in the experimental group was （1.52±0.28） points， which was lower than that in the control group for （2.74±0.46） points， and the difference was statistically significant （P<0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups （P>0.05）. Conclusion Lansoprazole and Pantoprazole in the treatment of gastric ulcer can significantly improve the clinical symptoms of patients， quickly relieve the pain of patients， the clinical effect is significant. Lansoprazole is superior to Pantoprazole in clinical efficacy， clinical symptom score and adverse reactions， its safety is high and it is worthy of clinical promotion.

[Key words] Lansoprazole; Pantoprazole; Gastric ulcer; Clinical efficacy

胃潰瘍（gastric ulcer）是臨床消化系統(tǒng)最常見的疾病之一，主要以腹痛、腹脹、反酸、胃脘部燒灼感等為癥狀，周期性、節(jié)律性疼痛是其最典型的臨床癥狀。其發(fā)病機制主要是胃酸、胃蛋白酶的侵襲作用與胃黏膜的保護作用平衡失調(diào)引起，幽門螺桿菌感染、非甾體消炎藥、胃排空異常是其常見的致病因素。此外，精神心理因素、應(yīng)激、不良生活習(xí)慣亦容易導(dǎo)致潰瘍的發(fā)生[1-2]。抑制胃酸分泌是治療胃潰瘍最關(guān)鍵的措施。近年來，隨著抑酸藥物的發(fā)展，越來越多的藥物被應(yīng)用于臨床，尤其是質(zhì)子泵抑制劑，如泮托拉唑、奧美拉唑、蘭索拉唑、雷貝拉唑等[3-4]。為探討胃潰瘍的治療，為臨床提供參考，本研究擬對我院住院的消化性潰瘍患者采用蘭索拉唑與泮托拉唑治療，并取得較好的效果，現(xiàn)報道如下。